{{Rsnum
|rsid=4344
|Gene=ACE
|Chromosome=17
|position=63489363
|Orientation=plus
|GMAF=0.4853
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ACE
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 26.5 | 46.9 | 26.5
| HCB | 52.6 | 39.4 | 8.0
| JPT | 32.7 | 51.3 | 15.9
| YRI | 15.0 | 49.7 | 35.4
| ASW | 5.3 | 66.7 | 28.1
| CHB | 52.6 | 39.4 | 8.0
| CHD | 41.3 | 48.6 | 10.1
| GIH | 34.7 | 50.5 | 14.9
| LWK | 19.1 | 48.2 | 32.7
| MEX | 41.4 | 34.5 | 24.1
| MKK | 9.0 | 50.6 | 40.4
| TSI | 11.8 | 44.1 | 44.1
| HapMapRevision=28
}}This SNP in the [[ACE]] gene, also known as G12269A, is reported to influence how quickly African Americans respond to the anti-hypertensive drug [[ramipril]]. [[rs4344(A;A)]] and [[rs4344(G;G)]] homozygotes are able to reach lower blood pressure levels upon treatment with [[ramipril]] sooner than [[rs4344(A;G)]] heterozygotes. The odds ratio reported for this study, comparing both homozygotes to heterozygotes, is 1.86 (CI: 1.32-3.23). {{PMID|17885551|OA=1
}}

Note that this SNP is in almost complete linkage disequilibrium with the insertion/deletion [[ACE]] gene SNP.

{{ neighbor
| rsid = 4646994
| distance = 824
}}

{{PMID Auto
|PMID=18194558
|Title=A hierarchical and modular approach to the discovery of robust associations in genome-wide association studies from pooled DNA samples.
|OA=1
}}

{{PMID Auto
|PMID=19963597
|Title=Visual exploration of genetic association with voxel-based imaging phenotypes in an MCI/AD study.
|OA=1
}}

{{PMID Auto
|PMID=20215856
|Title=Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head.
|OA=1
}}

{{PMID Auto
|PMID=21052031
|Title=Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}